Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10265114 | 1.00 | ALDH1A1 (0.48) | ALDH1A1NPC1CASP3KMT2AMEN1 | |
| SCHEMBL12318187 | 0.88 | MAPT (0.40) | ALDH1A1NPC1CASP3MAPTIDH1 | |
| SCHEMBL10264244 | 0.88 | MAPT (0.40) | ALDH1A1NPC1CASP3MAPTIDH1 | |
| SCHEMBL10205157 | 0.87 | KMT2A (0.49) | ALDH1A1NPC1KMT2AMAPTIDH1 | |
| SCHEMBL24457797 | 0.87 | POLB (0.40) | ALDH1A1NPC1KMT2AMEN1MAPT | |
| SCHEMBL8597022 | 0.86 | ATM (0.42) | KMT2AMEN1MAPT | |
| SCHEMBL7828421 | 0.86 | ATM (0.42) | KMT2AMEN1MAPT | |
| Water SCHEMBL8600954 | 0.85 | ATM (0.42) | KMT2AMEN1MAPT | |
| SCHEMBL8600205 | 0.84 | POLB (0.40) | ALDH1A1NPC1KMT2AMEN1MAPT | |
| SCHEMBL10372875 | 0.84 | GPR88 (0.39) | ALDH1A1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9677112-B2 | β-lactamase substrates and methods of their use for the diagnosis of tuberculosis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150167048-A1 | BETA-LACTAMASE SUBSTRATES AND METHODS OF THEIR USE FOR THE DIAGNOSIS OF TUBERCULOSIS | PGLS, ENGASE, BPHL | ALDH1A1 774/4885NPC1 2899/4885CASP3 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.